NCT05113693View on ClinicalTrials.gov

Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

November 25, 2021

Primary Completion Date

December 6, 2021

Study Completion Date

December 10, 2021

Conditions
Type 2 Diabetes
Interventions
DRUG

CKD-393

QD, PO

DRUG

CKD-501, D759, H053

QD, PO

Trial Locations (1)

Unknown

Chonbuk National University Hospital, Jeonju

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY